References
- Szecsi PB, Jørgensen M, Klajnbard A, et al. Haemostatic reference intervals in pregnancy. Thromb Haemost 2010;103:718–27
- Bellart J, Gilabert R, Fontcuberta J, et al. Fibrinolysis changes in normal pregnancy. J Perinat Med 1997;25:368–72
- McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol 2012;207:135.e1–6
- Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–44
- O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17:385–96
- Bremme K, Blombäck M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest 1996;41:20–6
- Girardi G. Role of tissue factor in pregnancy complications: crosstalk between coagulation and inflammation. Thromb Res 2011;127:S43–6
- Erez O, Romero R, Vaisbuch E, et al. High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. J Matern Fetal Neonatal Med 2010;23:23–33
- Erez O, Gotsch F, Mazaki-Tovi S, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med 2009;22:672–87
- Erez O, Espinoza J, Chaiworapongsa T, et al. A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. J Matern Fetal Neonatal Med 2008;21:732–44
- Smith SA, Antonaci FC, Woodhams BJ, Morrissey JH. Factor VIIA-antithrombin complexes in human plasma. XXI Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007. J Thromb Haemost 2007;5: Abstract O-S-040
- Chaiworapongsa T, Espinoza J, Yoshimatsu J, et al. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:368–73
- Erez O, Romero R, Hoppensteadt D, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008;21:855–69
- Siegbahn A. Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis 2000;30:41–7
- Drake TA, Morrissey JH, Edgington TA. Selective cellular expression of tissue factor in human tissues: implication for disorders of haemostasis and thrombosis. Am J Pathol 1989;134:1087–97
- Nemerson Y, Bach R. Tissue factor revisited. Prog Hemost Thromb 1982;6:237–61
- Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959–72
- Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993;81:2600–7
- Broze GJ Jr, Likert K, Higuchi D. Inhibition of factor VIIa/tissue factor by antithrormbin III and tissue factor pathway inhibitor. Blood 1993;82:1679–80
- Spiezia L, Rossetto V, Campello E, et al. Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thromb Haemost 2010;103:1188–92
- Spiezia L, Campello E, Gentilomo C, et al. Factor VIIa-antithrombin complexes in children with ischemic stroke. Thromb Res 2011;128:303–4
- Dusse LM, Carvalho MG, Cooper AJ, Lwaleed BA. Plasma factor VII: a potential marker of pre-eclampsia. Thromb Res 2011;127:e15–19
- Silveira A, Scanavini D, Boquist S, et al. Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease. Thromb Res 2012;130:221–5